This is an aggregated industry headline. Read the full story at BioPharma Dive →
Ipsen's $450M blood cancer drug; FDA selects first cohort for "pre-check" pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
By BioPharma Dive
· Jun 30, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
AstraZeneca will pay $34 million to resolve a lawsuit that alleged the company used illegal kickbacks to induc…
The WeekFierceBiotech ↗
Coming on the heels of a $130 million fundraising round just four months ago, bone-focused Angitia Biopharmace…
The WeekBriefing
Norwich Pharmaceuticals wins FDA approval for generic baloxavir marboxil, expanding affordable access to one-d…